Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage (GEM)

20. juli 2026 oppdatert av: Lamiya Mohiyiddeen, Fakih IVF Fertility Center

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer

Recurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both distressing and disorienting for affected families, particularly in settings such as the United Arab Emirates (UAE), where childbearing carries significant personal and cultural weight.

One leading hypothesis is that the underlying problem may not lie with the embryo itself, but with the way the mother's immune system responds to a developing pregnancy. Under normal physiological conditions, the maternal body must establish immune tolerance toward an embryo that is genetically half-foreign in origin. In some women, this tolerance mechanism may be impaired, reducing the likelihood that a pregnancy will successfully implant and progress.

This study will evaluate whether granulocyte colony-stimulating factor (G-CSF) a naturally occurring substance that normally stimulates the production of immune cells can help address this issue by modulating an overactive immune response and enhancing the uterine environment's capacity to support pregnancy. Notably, the study will enroll only women whose embryos have undergone genetic testing and been confirmed to be chromosomally normal. This eliminates embryo quality as a contributing factor to pregnancy loss and allows for a clearer assessment of whether G-CSF itself influences outcomes.

Earlier small-scale studies, including preliminary work conducted at our own centre, have shown encouraging results. This new trial builds on that foundation by enrolling a larger cohort, comparing G-CSF against a placebo (an inactive comparison treatment), and evaluating a simpler route of administration; subcutaneous injection, rather than direct infusion into the uterus. Together, these design features aim to provide the most reliable evidence to date on whether this treatment can meaningfully help couples affected by unexplained recurrent pregnancy loss.

Studieoversikt

Detaljert beskrivelse

Recurrent pregnancy loss (RPL) defined as two or more consecutive miscarriages before 20 weeks' gestation affects 1-2% of couples worldwide and remains one of the most distressing, poorly resolved conditions in reproductive medicine. In nearly half of cases, no definitive cause is identified. This burden is especially pronounced in the UAE and wider GCC region, where delayed childbearing and the strong sociocultural weight placed on fertility amplify the psychological, marital, and financial toll of unexplained RPL.

Despite decades of research, treatment remains largely empirical. Immune dysregulation is increasingly implicated as a central mechanism, with proposed pathways including aberrant natural killer (NK) cell activation, impaired regulatory T-cell expansion, inadequate decidualization, and an unfavorable Th1/Th17 cytokine profile, collectively compromising endometrial receptivity and embryo survival. However, most supporting studies have been small, uncontrolled, and unable to distinguish maternal immunological causes from embryo genetic abnormalities, leaving clinicians with few evidence-based options.

Granulocyte colony-stimulating factor (G-CSF), a hematopoietic cytokine with immunomodulatory and endometrial effects, has emerged as a promising candidate. Preclinical and early clinical data suggest it enhances endometrial proliferation and vascularization, supports folliculogenesis and oocyte competence, and promotes immune tolerance by expanding regulatory T-cells while reducing NK cell cytotoxicity. Small trials in both recurrent implantation failure and RPL populations have reported benefits in implantation and live birth rates, though results have been inconsistent - largely due to the same methodological limitations noted above, plus a failure to control for embryo aneuploidy as a confounder.

Our own retrospective pilot study of 19 patients receiving intrauterine G-CSF supports this rationale: 70.5% achieved a positive β-hCG, 66.7% progressed to ongoing pregnancy, and no adverse effects were observed. These findings demonstrate both feasibility and preliminary efficacy at our centre. However, intrauterine infusion is invasive, costly, and less patient-friendly; existing literature suggests subcutaneous administration may achieve comparable efficacy with greater convenience, but this route has not yet been evaluated in this specific population.

The GEM Trial is designed to resolve these open questions directly. By enrolling women with unexplained RPL undergoing IVF with preimplantation genetic testing for aneuploidy (PGT-A), the trial eliminates embryo chromosomal abnormality as a confounder, enabling a precise, mechanistically targeted test of the immunological hypothesis. It will be the first placebo-controlled, genetically controlled trial of G-CSF in this population, and the first to formally assess subcutaneous delivery.

If successful, the GEM Trial could establish a new standard of care for unexplained RPL offering a more convenient, evidence-based treatment option to thousands of couples and positioning the UAE as a global leader in reproductive immunology research.

Studietype

Intervensjonell

Registrering (Antatt)

150

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Abu Dhabi, De forente arabiske emirater
        • Rekruttering
        • Fakih IVF Fertility Centre LLC
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Fakih, MD
        • Hovedetterforsker:
          • Lamiya Mohiyiddeen, MD, FRCOG
        • Hovedetterforsker:
          • Yasmin Sajjad, MD, FRCOG

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion:

  1. Women aged 18-44 years
  2. ≥2 unexplained pregnancy losses
  3. Undergoing IVF with PGT-A tested embryos
  4. BMI 19-35 kg/m² 6.

Exclusion:

  1. Parental karyotype abnormalities
  2. Correctable uterine abnormalities
  3. Systemic autoimmune disease / thrombophilia
  4. Uncontrolled systemic illness (e.g. diabetes, infection)
  5. Previous G-CSF therapy
  6. Hypersensitivity to rhG-CSF or E. coli proteins
  7. HIV, malignancy within 5 years, or severe cardiovascular/respiratory history

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Recombinant G-CSF 130 mcg SC
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
Placebo komparator: Placebo Control: Placebo SC
Subcutaneous injection of placebo daily from embryo transfer until 12 weeks' gestation
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinical pregnancy rate
Tidsramme: From enrollment to 16 weeks gestation
Clinical pregnancy confirmation by transvaginal ultrasound at 16 weeks' gestation.
From enrollment to 16 weeks gestation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Live birth rate
Tidsramme: From enrollment to approximately 40 weeks' gestation.
From enrollment to approximately 40 weeks' gestation.
Ongoing Pregnancy Rate
Tidsramme: From 16 weeks to 34 weeks gestation.
16 - 34 weeks gestation by serial ultrasound.
From 16 weeks to 34 weeks gestation.
Early Pregnancy Loss rate
Tidsramme: From FET (Fetal Embryo Transfer) to 12 weeks gestation
Pregnancy loss confirmed by a transvaginal ultrasound.
From FET (Fetal Embryo Transfer) to 12 weeks gestation
Rate of Adverse pregnancy outcomes (APOs)
Tidsramme: From enrollment to approximately 40 weeks gestation
Rate of Miscarriage, stillbirth, neonatal outcomes (birth weight, NICU admission, congenital anomalies) and maternal outcomes assessed using several methods including transvaginal ultrasound and clinical assessment.
From enrollment to approximately 40 weeks gestation
Rate of Adverse events
Tidsramme: From enrollment up to approximately 40 weeks gestation (delivery)
Safety data including pregnancy related, fetal or maternal adverse events e.g. infections, cytopenias, hypersensitivity etc.
From enrollment up to approximately 40 weeks gestation (delivery)
Rate of immunogenicity
Tidsramme: From enrollment to up to approximately 40 weeks gestation (delivery)
Anti-drug antibody (ADA) formation (serology in subset).
From enrollment to up to approximately 40 weeks gestation (delivery)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. juli 2026

Primær fullføring (Antatt)

10. august 2027

Studiet fullført (Antatt)

10. oktober 2027

Datoer for studieregistrering

Først innsendt

14. juli 2026

Først innsendt som oppfylte QC-kriteriene

20. juli 2026

Først lagt ut (Faktiske)

24. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • FAKIH-2025-10
  • DOH/ADHRTC/2026/34566666666666 (Annen identifikator: Department of Health Abu Dhabi)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere